Ribavirin News and Research

RSS
Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

Further Reading

Experts must monitor new antiviral compounds for HCV treatment

Experts must monitor new antiviral compounds for HCV treatment

2 Apr 2011
Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

2 Apr 2011
MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

MSD's Victrelis Phase III trial final results against HCV presented at EASL meeting

2 Apr 2011
Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

2 Apr 2011
Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

2 Apr 2011
Series of new clinical trials confirm range of viable treatment options for HCV patients

Series of new clinical trials confirm range of viable treatment options for HCV patients

2 Apr 2011
Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

Encouraging early data from HCV vaccine phase I trial presented at International Liver Congress

2 Apr 2011
Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

1 Apr 2011
Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

1 Apr 2011
New data confirms antiviral activity of fluvastatin in patients with HCV

New data confirms antiviral activity of fluvastatin in patients with HCV

1 Apr 2011
Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

1 Apr 2011
Vertex announces final results from Phase 3 REALIZE study against HCV

Vertex announces final results from Phase 3 REALIZE study against HCV

1 Apr 2011
Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

Conatus CTS-1027 Phase 2 trial results against HCV presented at EASL meeting

1 Apr 2011
Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

Vertex announces interim results from VX-222 ongoing Phase 2 study against hepatitis C

31 Mar 2011
Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

Positive top-line data from Inhibitex INX-189 Phase 1b trial against HCV

31 Mar 2011
NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

NEJM publishes MSD's VICTRELIS two pivotal Phase III studies against HCV

31 Mar 2011
Boceprevir drug can help cure hard-to-treat hepatitis C

Boceprevir drug can help cure hard-to-treat hepatitis C

31 Mar 2011
Three-drug cocktail more effective against hepatitis C virus

Three-drug cocktail more effective against hepatitis C virus

31 Mar 2011
Pharmasset commences PSI-7977 Phase 2b study against HCV

Pharmasset commences PSI-7977 Phase 2b study against HCV

30 Mar 2011
iTherX commences ITX-5061 Phase 1b study in patients with HCV

iTherX commences ITX-5061 Phase 1b study in patients with HCV

16 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback